C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease

C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease
复制标题

DOI:
10.1016/j.jalz.2015.05.012
复制
发表时间:
2015-12-01
影响因子:
14
通讯作者:
Vanmechelen, Eugeen
Vanmechelen, Eugeen
中科院分区:
医学1区
文献类型:
--
作者:
De Vos, Ann;Jacobs, Dirk;Vanmechelen, Eugeen

文献摘要

被引文献

相似文献

生物标志物监测突触变性/丧失将对阿尔茨海默病(AD)的诊断有价值。突触后蛋白神经粒蛋白可能是一种很有前途的脑脊液生物标志物,但尚未被评估为血浆生物标志物。方法:使用内部设计的针对神经颗粒蛋白c末端的原型酶联免疫吸附试验(ELISA),我们研究了配对CSF/血浆样本中的神经颗粒蛋白,对照(n = 29)和因AD引起的MCI或痴呆患者(总n = 59)。结果:AD患者脑脊液神经颗粒蛋白升高,与脑脊液tau呈正相关,脑脊液神经颗粒蛋白(和tau)与CSF fa β (1-42)/ a β(1-40)呈负相关。血浆神经颗粒蛋白在对照组和AD组之间没有差异。此外,排除后者的混杂效应,脑脊液和血浆神经颗粒蛋白之间没有相关性。讨论:这项研究加强了神经颗粒蛋白作为AD CSF生物标志物的潜力,现在需要在更大规模的研究中进行验证。正如所描述的ELISA所证明的那样,可以使用直接的免疫测定法作为工具。(C) 2015年作者。由爱思唯尔公司代表阿尔茨海默病协会出版。这是一篇基于CC BY-NC-ND许可的开放获取文章。
Introduction: Biomarkers monitoring synaptic degeneration/loss would be valuable for Alzheimer's disease (AD) diagnosis. Postsynaptic protein neurogranin may be a promising cerebrospinal fluid (CSF) biomarker but has not yet been evaluated as a plasma biomarker.Methods: Using an in-house designed prototype enzyme-linked immunosorbent assay (ELISA) targeting neurogranin C-terminally, we studied neurogranin in paired CSF/plasma samples of controls (n = 29) versus patients experiencing MCI, or dementia, due to AD (in total n = 59).Results: CSF neurogranin was increased in AD and positively correlated with CSF tau, whereas there was a negative relationship between CSF neurogranin (and tau) and CSFA beta(1-42)/A beta(1-40). No differences were detected in plasma neurogranin between controls and AD. Also, there was no correlation between CSF and plasma neurogranin, excluding confounding effects of the latter.Discussion: This study strengthens the potential of neurogranin as an AD CSF biomarker, which now needs validation in larger studies. As tools, straightforward immunoassays can be used, as demonstrated by the described ELISA. (C) 2015 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer's Association. This is an open access article under the CC BY-NC-ND license.